StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) company profile

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

About United Therapeutics

Pharmaceutical Preparations, SIC 2834

United Therapeutics Corporation is a biotechnology public benefit corporation that develops and commercializes therapies for rare, life-threatening conditions and develops organ manufacturing technologies. Its primary commercial focus is pulmonary arterial hypertension, which it addresses through treprostinil-based therapies including Tyvaso DPI, nebulized Tyvaso, Remodulin, and Orenitram, alongside the phosphodiesterase type 5 inhibitor Adcirca. Nebulized Tyvaso and Tyvaso DPI are also indicated to treat pulmonary hypertension associated with interstitial lung disease. Additionally, the company markets Unituxin, an oncology biologic targeting high-risk neuroblastoma. The company distributes its products primarily to specialty pharmaceutical distributors within the United States and to pharmaceutical distributors internationally.

The company operates globally, selling commercial products across the United States, Canada, Japan, most of Europe, and selected countries in Asia, Latin America, and the Middle East. United Therapeutics maintains principal executive offices in Silver Spring, Maryland, and Durham, North Carolina.

Summary of the business section of United Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
UNITED THERAPEUTICS Corp
Founded
1996
Headquarters
Silver Spring, MD
Address
1000 Spring St 20910
Phone
(301) 608-9292
Employees
1,400, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Tysons, Virginia

Stock & identifiers

Ticker
UTHR
Exchange
Nasdaq
IPO date
Jun 17, 1999
Shares outstanding
43M, Jul 29, 2026
Public float
$11.23B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Sep 23, 2009
SEC CIK
1082554
CUSIP
91307C102
ISIN
US91307C1027
FIGI
BBG000BV4XJ1
Share class FIGI
BBG001S8RV10
LEI
5299005C4HZL4UWROC14
EIN
52-1984749

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martine A. RothblattChairperson & CEO, Director365,122
Paul A. MahonEVP & GENERAL COUNSEL45,172
James EdgemondCFO AND TREASURER25,506
Michael BenkowitzPRESIDENT AND COO36,462
Christopher PatuskyDirector3,240
Nilda MesaDirector5,580
Tommy G. ThompsonDirector22,480
Judy D. OlianDirector5,555
Kevin TraceyDirector–
Jan MalcolmDirector450
Linda MaxwellDirector2,000
Christopher CauseyDirector4,190
Louis W. SullivanDirector4,440
Ray KurzweilDirector13,320
Victor J. DzauDirector–
Richard GiltnerDirector21,884
Raymond DwekDirector4,750

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$18.04M$149.88M$9.42M$321$201
FY2024$23.01M$120.26M$10.01M$232$156
FY2023$16.96M-$10.81M$7.00M$145$144
FY2022$5.32M$41.19M$2.38M$183$139
FY2021$3.51M$50.43M$1.96M$142$124
FY2020$4.81M$49.92M$4.15M$172$111

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Martine Rothblatt
Chairperson and Chief Executive Officer
$1.55M$6.07M$6.08M$4.28M$68.30K$18.04M-22%
James Edgemond
Chief Financial Officer and Treasurer
$955.77K$1.95M$1.95M$1.62M$1.87M$8.35M-9%
Michael Benkowitz
President and Chief Operating Officer
$1.44M$3.12M$3.12M$3.32M$3.38M$14.39M+4%
Paul Mahon
Executive Vice President and General Counsel
$964.23K$1.52M$1.52M$1.50M$29.50K$5.53M-21%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 1,400 employees working across our 15 locations worldwide.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?